Varda Space Industries Launches W-7 to Study Cancer Drug Crystallization in Orbit
Varda Space Industries Launches W-7 to Study Cancer Drug Crystallization in Orbit
PR Newswire
EL SEGUNDO, Calif., Oct. 20, 2026
The company's third launch this month will investigate how microgravity can unlock the therapeutic potential of a new class of cancer medicines.
EL SEGUNDO, Calif., Oct. 20, 2026 /PRNewswire/ -- Varda Space Industries, the leading microgravity-enabled life sciences and hypersonic reentry company, today launched the W-7 vehicle into orbit. The flight is Varda's third launch this month and its fourth of 2026, underscoring the company's rapidly maturing operational cadence and its commitment to making orbital processing a routine part of the drug development pipeline.
The W-7 payload will mix liquids with an active pharmaceutical ingredient to investigate how microgravity can improve drug solubility for patients in a class of next-generation cancer medicines known as PROTACs, or Proteolysis-Targeting Chimeras. Rather than simply blocking disease-causing proteins the way traditional drugs do, PROTACs are designed to co-opt the cell's own waste-disposal machinery, tagging harmful proteins for complete destruction.
Despite their potential, PROTACs are large, complex molecules that tend to dissolve poorly in biological fluids, making them difficult to formulate into medicines the body can absorb. Poor solubility is one of the leading reasons promising drug candidates fail to become viable treatments.
In the absence of gravity-driven convection and sedimentation, molecules can form crystals with different structures and properties impossible to achieve on Earth, including forms that are significantly more soluble. W-7 will expose a PROTAC compound to microgravity conditions as it crystalizes during its time in orbit. The resulting crystals will return to Earth for analysis on improved solubility, and could translate into a more absorbable, more effective medicine.
If Varda's W-7 mission demonstrates that microgravity can yield PROTAC crystal forms with meaningfully better solubility profiles, it could open a path toward clinical development for an entire class of compounds that remain difficult to formulate.
"The most sophisticated molecule in the world doesn't help a patient if it can't be absorbed by the body," said Michael Reilly, Chief Strategy Officer at Varda Space Industries. "Varda is finding new ways to make powerful medicines work better for the people who need them. With W-7, we're testing unique physics of microgravity in pursuit of solving a formulation problem that limits an entire class of cancer drugs."
By treating low Earth orbit as manufacturing platform available on a routine basis, Varda is enabling the development of the first drug made in space to benefit patients on Earth.
About Varda
Varda Space Industries is a microgravity-enabled life sciences company building the infrastructure for a thriving orbital economy, from in-orbit pharmaceutical processing to reliable and economical hypersonic reentry capsules. Varda is headquartered in El Segundo, Calif. and also has offices in Washington, D.C. and Huntsville, Ala. Follow Varda on X (@vardaspace), Instagram (@vardaspaceindustries), and LinkedIn.
Media Inquiries: Alex Pearlman, press@varda.com
SOURCE Varda Space Industries Inc.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Growth Stocks to Buy While They’re Still Undervalued
3 of the Best Core Stocks to Own
3 Great New ETFs From 2026
The 10 Best Companies to Invest in Now
United States